Akira Nakakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akira Nakakami has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Manabu Futamura
Department of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan
3 shared publications - Yoshihisa Tokumaru
Department of Breast Surgery, Gifu University Hospital , Gifu, Gifu, 501-1194
3 shared publications Ryutaro Mori
Department of Medical Informatics, Gifu University Hospital, Gifu, 501-1194, Japan
2 shared publications- Akiyo Yoshimura
Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681
1 shared publication - Ayaka Isogai
Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
1 shared publication - Ayumi Kataoka
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Springer Nature in Breast Cancer
- Vol. 33 (1) , 72-79
Impact of breast density on the efficacy of radiofrequency ablation in early-stage breast cancer
Background: Radiofrequency ablation (RFA) is a minimally invasive technique employed in the management of small breast tumors. RFA involves the delivery of a high-frequency current through a needle electrode under ultrasound guidance. In Japan, RFA has been covered by insurance since 2023 as a localized treatment option for early-stage breast cancers. Methods: We retrospectively analyzed the data of patients who underwent RFA at our institution between February 2016 and March 2025. Breast density was classified into four categories based on the Breast Imaging Reporting and Data System. Associations between breast density and RFA parameters, including ablation temperature, time, and impedance, were evaluated. Results: A total of 50 breasts in 49 female patients were treated with RFA. The mean peak ablation temperature recorded after the cooling break was 81.0 ± 8.0 °C. Increased breast density was significantly associated with high temperatures. The mean ablation time until break was 446 ± 139 s, indicating a trend toward prolonged durations in cases involving denser breast tissue. The mean initial and final impedance values were 208 ± 72.3 Ω and 161 ± 66.5 Ω, respectively. Fat-rich breasts exhibited significantly higher impedance values at both time points. Conclusion: Fatty breast tissue is associated with higher impedance, lower peak temperatures, and shorter ablation times, potentially resulting in insufficient ablation. Breast density should be considered when planning RFA to ensure optimal treatment efficacy.
- 22 September 2025
- Published by Springer Nature in Breast Cancer
- Vol. 33 (1) , 72-79
Open AccessImpact of breast density on the efficacy of radiofrequency ablation in early-stage breast cancer
Background: Radiofrequency ablation (RFA) is a minimally invasive technique employed in the management of small breast tumors. RFA involves the delivery of a high-frequency current through a needle electrode under ultrasound guidance. In Japan, RFA has been covered by insurance since 2023 as a localized treatment option for early-stage breast cancers. Methods: We retrospectively analyzed the data of patients who underwent RFA at our institution between February 2016 and March 2025. Breast density was classified into four categories based on the Breast Imaging Reporting and Data System. Associations between breast density and RFA parameters, including ablation temperature, time, and impedance, were evaluated. Results: A total of 50 breasts in 49 female patients were treated with RFA. The mean peak ablation temperature recorded after the cooling break was 81.0 ± 8.0 °C. Increased breast density was significantly associated with high temperatures. The mean ablation time until break was 446 ± 139 s, indicating a trend toward prolonged durations in cases involving denser breast tissue. The mean initial and final impedance values were 208 ± 72.3 Ω and 161 ± 66.5 Ω, respectively. Fat-rich breasts exhibited significantly higher impedance values at both time points. Conclusion: Fatty breast tissue is associated with higher impedance, lower peak temperatures, and shorter ablation times, potentially resulting in insufficient ablation. Breast density should be considered when planning RFA to ensure optimal treatment efficacy.
- Open Access
Application of N-NOSE for Evaluating the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Background: Breast cancer remains a leading cause of cancer-related deaths despite advances in its diagnosis and treatment. Accurate evaluation of the response to neoadjuvant chemotherapy (NAC), especially in HER2-positive and triple-negative subtypes, is critical. The current methods, including imaging and liquid biopsies, have limitations. N-NOSE, a novel urine-based cancer screening test using Caenorhabditis elegans (C. elegans) chemotaxis, offers a non-invasive alternative. This study investigates the potential of N-NOSE to predict the NAC response in breast cancer patients for improved treatment evaluations. Materials and Methods: This prospective study enrolled 36 breast cancer patients undergoing NAC and surgery to assess the predictive power of the N-NOSE method using urine samples. A chemotaxis analysis of C. elegans was used to calculate the index reduction scores (IRS1–3), reflecting the changes in tumor-related odorants across the treatment stages. Results: Between August 2020 and May 2023, 36 breast cancer patients were enrolled to evaluate the predictive value of N-NOSE IRSs for NAC response. A pathological complete response (pCR) was achieved in 36.1% of the patients. Among the three IRS types analyzed in the 35 patients, IRS3, which showed the IRS at pre-treatment minus that after surgery, showed the highest predictive performance for a pCR, with an AUC of 0.75, indicating its potential utility as a non-invasive biomarker for treatment response evaluations. Conclusions: Index reduction scores evaluated using the N-NOSE method may reflect the efficacy of NAC in breast cancer patients. Future large-scale and multi-institutional prospective studies are warranted.
Open AccessApplication of N-NOSE for Evaluating the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Background: Breast cancer remains a leading cause of cancer-related deaths despite advances in its diagnosis and treatment. Accurate evaluation of the response to neoadjuvant chemotherapy (NAC), especially in HER2-positive and triple-negative subtypes, is critical. The current methods, including imaging and liquid biopsies, have limitations. N-NOSE, a novel urine-based cancer screening test using Caenorhabditis elegans (C. elegans) chemotaxis, offers a non-invasive alternative. This study investigates the potential of N-NOSE to predict the NAC response in breast cancer patients for improved treatment evaluations. Materials and Methods: This prospective study enrolled 36 breast cancer patients undergoing NAC and surgery to assess the predictive power of the N-NOSE method using urine samples. A chemotaxis analysis of C. elegans was used to calculate the index reduction scores (IRS1–3), reflecting the changes in tumor-related odorants across the treatment stages. Results: Between August 2020 and May 2023, 36 breast cancer patients were enrolled to evaluate the predictive value of N-NOSE IRSs for NAC response. A pathological complete response (pCR) was achieved in 36.1% of the patients. Among the three IRS types analyzed in the 35 patients, IRS3, which showed the IRS at pre-treatment minus that after surgery, showed the highest predictive performance for a pCR, with an AUC of 0.75, indicating its potential utility as a non-invasive biomarker for treatment response evaluations. Conclusions: Index reduction scores evaluated using the N-NOSE method may reflect the efficacy of NAC in breast cancer patients. Future large-scale and multi-institutional prospective studies are warranted.
- 26 May 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (2) , 253-261
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
Purpose Trastuzumab deruxtecan (T-DXd) can improve the prognosis of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, data on treatment recommendations after T-DXd are lacking. Thus, this study aimed to evaluate the treatment options after T-DXd and their effectiveness. Methods Patients with HER2-positive MBC were included in this study. Data from clinical records were retrospectively analyzed. The primary outcome was time to treatment failure (TTF). Secondary endpoints were TTF of each treatment and first-line treatment after interstitial lung disease (ILD) and overall survival (OS). Results A total of 29 patients were included. Among them, 18 (62%) were hormone receptor-positive. All patients had a median TTF (mTTF) of 3.5 months (95% confidence interval (CI) 2.1–10.03). The mTTF of each treatment, including HER2 tyrosine kinase inhibitor (HER2 TKI), other anti-HER2 treatments, and other treatments, was 2.6, 8.8, and 3.8 months, respectively. No significant differences were observed between treatments, but regimens that include trastuzumab showed a longer TTF than TKI. However, the mTTF among patients who developed T-DXd-related ILD was 2.33 months (95% CI 0.7–not reached), which was shorter than that among those who did not develop ILD (3.83 months, 95% CI 2.1–10.03, hazard ratio: 2.046, 95% CI 0.760–5.507, p = 0.258). The median OS was 14.9 months (95% CI 11.07–29.17). Conclusion Treatments after T-DXd showed a shorter mTTF. Regimens that include trastuzumab may be more effective post-T-DXd treatment than HER2 TKI. Further data are needed to establish the best sequential treatment after T-DXd.
- 26 May 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (2) , 253-261
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
Purpose Trastuzumab deruxtecan (T-DXd) can improve the prognosis of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, data on treatment recommendations after T-DXd are lacking. Thus, this study aimed to evaluate the treatment options after T-DXd and their effectiveness. Methods Patients with HER2-positive MBC were included in this study. Data from clinical records were retrospectively analyzed. The primary outcome was time to treatment failure (TTF). Secondary endpoints were TTF of each treatment and first-line treatment after interstitial lung disease (ILD) and overall survival (OS). Results A total of 29 patients were included. Among them, 18 (62%) were hormone receptor-positive. All patients had a median TTF (mTTF) of 3.5 months (95% confidence interval (CI) 2.1–10.03). The mTTF of each treatment, including HER2 tyrosine kinase inhibitor (HER2 TKI), other anti-HER2 treatments, and other treatments, was 2.6, 8.8, and 3.8 months, respectively. No significant differences were observed between treatments, but regimens that include trastuzumab showed a longer TTF than TKI. However, the mTTF among patients who developed T-DXd-related ILD was 2.33 months (95% CI 0.7–not reached), which was shorter than that among those who did not develop ILD (3.83 months, 95% CI 2.1–10.03, hazard ratio: 2.046, 95% CI 0.760–5.507, p = 0.258). The median OS was 14.9 months (95% CI 11.07–29.17). Conclusion Treatments after T-DXd showed a shorter mTTF. Regimens that include trastuzumab may be more effective post-T-DXd treatment than HER2 TKI. Further data are needed to establish the best sequential treatment after T-DXd.
- Open Access
- 1 January 2021
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 46 (4) , 444-449
A Huge Phyllodes Tumor of the Breast in a Case of Myotonic Dystrophy Type 1
筋強直性ジストロフィー1型(Myotonic dystrophy type 1,DM1)は,ミオトニア現象を伴う常染色体優性遺伝性筋疾患である.腫瘍の合併率が高い点で重要な疾患であるが,心合併症や呼吸不全の進行により腫瘍に対する外科手術困難の原因にもなる.そのため,DM1と腫瘍の両者を評価し,治療方針を決定することが重要である.われわれは,DM1に巨大葉状腫瘍を合併した症例を経験したので報告する.症例は39歳女性,特発性慢性呼吸不全の診断のもと,近医で経過観察されていた.左乳房腫瘤が約20cmまで増大し,治療目的に当科に紹介となった.遺伝子検査からDM1と診断し,左乳房腫瘤は,葉状腫瘍と診断した.外科手術を検討したが,DM1によるⅡ型呼吸不全の増悪により,手術療法は断念し,看取りの方針とした.DM1は,腫瘍合併リスクが高いことから,腫瘍早期発見のため適切なスクリーニングの施行,治療法の選択や治療時期の検討が必要である.
- 1 January 2021
- Published by Japanese College of Surgeons in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
- Vol. 46 (4) , 444-449
Open AccessA Huge Phyllodes Tumor of the Breast in a Case of Myotonic Dystrophy Type 1
筋強直性ジストロフィー1型(Myotonic dystrophy type 1,DM1)は,ミオトニア現象を伴う常染色体優性遺伝性筋疾患である.腫瘍の合併率が高い点で重要な疾患であるが,心合併症や呼吸不全の進行により腫瘍に対する外科手術困難の原因にもなる.そのため,DM1と腫瘍の両者を評価し,治療方針を決定することが重要である.われわれは,DM1に巨大葉状腫瘍を合併した症例を経験したので報告する.症例は39歳女性,特発性慢性呼吸不全の診断のもと,近医で経過観察されていた.左乳房腫瘤が約20cmまで増大し,治療目的に当科に紹介となった.遺伝子検査からDM1と診断し,左乳房腫瘤は,葉状腫瘍と診断した.外科手術を検討したが,DM1によるⅡ型呼吸不全の増悪により,手術療法は断念し,看取りの方針とした.DM1は,腫瘍合併リスクが高いことから,腫瘍早期発見のため適切なスクリーニングの施行,治療法の選択や治療時期の検討が必要である.